Translational Development Acquisition Corp. (NASDAQ: TDAC) is a Financial Services company (Shell Companies) with a market capitalization of $268M. The Maz Rating grades it against the other companies in its sector.
Translational Development Acquisition Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.87, Translational Development Acquisition Corp. trades at 1.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -3.4%, return on invested capital of -1.0% and a free cash flow yield of -0.4%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 0.03. Over the past 52 weeks the share price ranged from $10.41 to $10.95, with a beta of 0.01.
Translational Development Acquisition Corp. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Translational Development Acquisition Corp. (TDAC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.19% / 30% · (Cash+Inv) / Mkt Cap (36m) 87.9% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.19% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.05% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.19% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.05% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.58% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 0.03% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 1.35% / 33.33% · (Cash+ST Inv) / Total Assets 0.05% / 33.33% · (Cash+Recv) / Total Assets 0.05% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Translational Development Acquisition Corp. (TDAC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
No. Translational Development Acquisition Corp. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Translational Development Acquisition Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.